InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
7
T+90 hit rate
0%
T+90 mean return
-7.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Schilke Tobin, Chief Financial Officer. Director active across 2 companies, notably Revance Therapeutics, Inc.. Aggregated, 34 filings have been published. Split: 0 buy · 7 sells. Total volume traded: €535k. History available since 30 June 2021. The latest transaction was disclosed on 10 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations34 total
52,000 shares0Common StockSEC:0000950170-25-037200:0
97,999 shares@ US$3.6526.6% of flowCommon StockSEC:0000950170-25-015362:0
6,888 shares0Common StockSEC:0000950170-25-014824:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-25-000005:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-24-000103:0
3,822 shares@ US$5.3051.4% of flowCommon StockSEC:0001479290-24-000066:0
17,447 shares0Common StockSEC:0001479290-24-000051:0
96,667 shares0Common StockSEC:0001479290-24-000015:0
434 shares@ US$7.470.2% of flowCommon StockSEC:0001479290-24-000005:0
22,620 shares0Common StockSEC:0001479290-23-000099:0
769 shares@ US$15.6060.8% of flowCommon StockSEC:0001479290-23-000083:0
2,701 shares@ US$30.575.9% of flowCommon StockSEC:0001479290-23-000077:0
42,349 shares0Common StockSEC:0001479290-23-000075:0
3,201 shares@ US$31.707.1% of flowCommon StockSEC:0001479290-23-000056:0
3,201 shares@ US$32.157.2% of flowCommon StockSEC:0001479290-23-000053:0
3,739 shares@ US$30.658.2% of flowCommon StockSEC:0001479290-23-000041:0
42,349 shares0Common StockSEC:0001479290-23-000036:0
3,201 shares@ US$33.507.8% of flowCommon StockSEC:0001479290-23-000031:0
2,085 shares@ US$33.215.0% of flowCommon StockSEC:0001479290-23-000018:0
3,201 shares@ US$34.607.8% of flowCommon StockSEC:0001479290-23-000015:0
1,000 shares@ US$31.002.2% of flowCommon StockSEC:0001479290-23-000012:0
1,701 shares@ US$25.003.1% of flowCommon StockSEC:0001479290-23-000007:0
645 shares@ US$12.18050.6% of flowCommon StockSEC:0001479290-23-000003:0
1,557 shares@ US$21.502.4% of flowCommon StockSEC:0001479290-22-000106:0
965 shares@ US$11.7470.8% of flowCommon StockSEC:0001479290-22-000072:0
25 of 34 declarations
About Schilke Tobin
Tobin Schilke is the Chief Financial Officer at Revance Therapeutics, Inc. He is responsible for financial management and corporate strategy. Schilke plays a key role in optimizing financial performance and strategic decision-making. His expertise is essential for ensuring the growth and profitability of the company.
